Friday, May 22, 2015 12:01:39 AM
WAIT and see what happens. Then buy -even if you must some stock at 3.7 but a fraction of what you plan to buy then average in. You want stock at a discount. Example. I plan to add ISR into my portfolio. I want it to be 5% of my total. My portfolio is 100,000.
5% equals 5000. Stock is at 3.7 I can't wait (even though you should because it already ran up 85%). So you buy 10% at 3.7.
Then you see the stock come in you buy 20% at the close say 2.20.
Then you wait another day or more because you have no idea where the stock will settle. When it establishes a base or news comes out and the stock rebounds you add another 30% or not depending.Let's say the company refutes a negative news story and the stock rebounds on the open you buy the 30% as I stated. You have 40 % to go. Best to wait for a few days or weeks to add the remaining 40%.And that you can do in pieces. By buying in increments you avoid that sick feeling of a large loss that frequently happens when you DO NOT THINK and plan rationally. So you bought 5000 at 3.7 that's 18,500. And at 2 you are down 8500 and are ready to sell at 3 for a 2 or 4 day loss at 3500 with the sinking feeling of how stupid you feel. Based on what- being undisciplined and emotional.\
Stop and think before you hit the buy and sell buttons.
Then you would not have to write "Don't know what I am going to do.. Disturbed badly."
If you want to make money in any market --STOP,THINK AND PLAN.
I hope this helps. And I am only writing this because I have been there many years ago.
Recent CATX News
- Perspective Therapeutics to Participate at Upcoming April Investor Conferences • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Perspective Therapeutics Announces $87.4 Million Private Placement • GlobeNewswire Inc. • 03/04/2024 02:45:00 PM
- Perspective Therapeutics to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement • GlobeNewswire Inc. • 01/22/2024 09:05:00 PM
- Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement • GlobeNewswire Inc. • 01/18/2024 12:00:00 PM
- Perspective Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 01/17/2024 09:05:00 PM
- Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01 • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Another Healthcare Stock Stealing The Show • AllPennyStocks.com • 01/09/2024 09:10:00 PM
- Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment • GlobeNewswire Inc. • 01/05/2024 01:00:00 PM
- Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Perspective Therapeutics Divests Brachytherapy Business • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM